1. Home
  2. APRE vs SONM Comparison

APRE vs SONM Comparison

Compare APRE & SONM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APRE
  • SONM
  • Stock Information
  • Founded
  • APRE 2006
  • SONM 1999
  • Country
  • APRE United States
  • SONM United States
  • Employees
  • APRE N/A
  • SONM N/A
  • Industry
  • APRE Biotechnology: Biological Products (No Diagnostic Substances)
  • SONM Telecommunications Equipment
  • Sector
  • APRE Health Care
  • SONM Telecommunications
  • Exchange
  • APRE Nasdaq
  • SONM Nasdaq
  • Market Cap
  • APRE 10.0M
  • SONM 10.2M
  • IPO Year
  • APRE 2019
  • SONM 2019
  • Fundamental
  • Price
  • APRE $1.80
  • SONM $0.66
  • Analyst Decision
  • APRE Strong Buy
  • SONM
  • Analyst Count
  • APRE 2
  • SONM 0
  • Target Price
  • APRE $15.50
  • SONM N/A
  • AVG Volume (30 Days)
  • APRE 50.9K
  • SONM 12.3M
  • Earning Date
  • APRE 08-11-2025
  • SONM 08-08-2025
  • Dividend Yield
  • APRE N/A
  • SONM N/A
  • EPS Growth
  • APRE N/A
  • SONM N/A
  • EPS
  • APRE N/A
  • SONM N/A
  • Revenue
  • APRE $1,284,475.00
  • SONM $58,243,000.00
  • Revenue This Year
  • APRE N/A
  • SONM $127.68
  • Revenue Next Year
  • APRE N/A
  • SONM N/A
  • P/E Ratio
  • APRE N/A
  • SONM N/A
  • Revenue Growth
  • APRE 33.27
  • SONM N/A
  • 52 Week Low
  • APRE $1.41
  • SONM $0.60
  • 52 Week High
  • APRE $5.01
  • SONM $9.21
  • Technical
  • Relative Strength Index (RSI)
  • APRE 49.58
  • SONM 39.12
  • Support Level
  • APRE $1.64
  • SONM $0.60
  • Resistance Level
  • APRE $1.81
  • SONM $2.08
  • Average True Range (ATR)
  • APRE 0.15
  • SONM 0.32
  • MACD
  • APRE -0.01
  • SONM -0.07
  • Stochastic Oscillator
  • APRE 51.76
  • SONM 4.48

About APRE Aprea Therapeutics Inc. Common stock

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

About SONM Sonim Technologies Inc.

Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the Canada, and to Bell, Rogers, and Telus and Rogers, Telstra in Australia. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.

Share on Social Networks: